• Users Online: 161
  • Print this page
  • Email this page
ORIGINAL ARTICLE
Year : 2020  |  Volume : 8  |  Issue : 1  |  Page : 15-18

Study of atazanavir-induced hyperbilirubinemia among HIV patients on second-line anti-retroviral therapy


Department of Medicine, BMCRI, Bengaluru, Karnataka, India

Correspondence Address:
Dr. G N Devamsh
Department of Medicine, Victoria Hospital, Bangalore Medical College and Research Institute, K R Market, Bengaluru - 560 002, Karnataka
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/AJIM.AJIM_32_19

Rights and Permissions

Introduction: Ritonavir-boosted atazanavir (ATV/r) is the preferred second-line protease inhibitor option for HIV patients as per the NACO guidelines. Atazanavir is a protease inhibitor with several advantages including once-daily dosing, low pill burden, and favorable effect on lipid profile compared with other protease inhibitors. Atazanavir-induced hyperbilirubinemia is not widely studied in the Indian population. Aim: The aim is to study the occurrence of atazanavir-induced hyperbilirubinemia in HIV patients receiving second-line antiretroviral therapy (ART) and its outcome. Materials and Methods: One hundred and ten HIV patients treated with ATV/r-based second-line anti-retroviral regimen at a tertiary care hospital were included in the study and followed up for at least 12 months. Liver function tests were measured at baseline (at the time of initiation of ATV/r), at 6 months and 12 months of second-line ART. Results: The cumulative incidence of hyperbilirubinemia in the study population was 42.72% (n = 47). However, atazanavir-induced hyperbilirubinemia was self-limiting and did not mandate change in regimen. Conclusion: A significant number of patients on ATV/r-based second-line ART developed indirect hyperbilirubinemia. There was no significant elevation in liver enzymes. Most of the patients tolerated ATV/r-based regimen well and there was no need for discontinuation/change of regimen. Patients on ATV/r-based regimen must be followed up closely and counseled regarding adherence to therapy.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed37    
    Printed0    
    Emailed0    
    PDF Downloaded8    
    Comments [Add]    

Recommend this journal